RPRX Royalty Pharma plc
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company has research and development funding collaboration to advance the development of JNJ-4804, an investigational medicine for autoimmune diseases. The company was founded in 1996 and is based in New York, New York.…
Industry Peers
BiotechnologyKey Statistics
About Royalty Pharma (NASDAQ: RPRX)
›
Royalty Pharma (NASDAQ: RPRX) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 100 employees.
The shares were at 67.72 USD on 19 November 2026, up 70.1% over 52 weeks. Its 52-week range is 37.31 USD to 70.37 USD: the price is 3.8% below the high and 81.5% above the low.
At a market capitalisation of 38.94B USD, it trades at 44.3 times trailing earnings and 11.5 times forward earnings. The median trailing P/E of its 13 largest Biotechnology peers is 33.5, a premium of 32% for RPRX. It pays a dividend yielding 1.37% (it pays out 60% of its earnings), against a median of 0.51% among the dividend payers in that peer group.
Royalty Pharma reports return on equity of 11.9%, an operating margin of 64.4% and revenue up 13.3% year over year.
Its debt exceeds its cash by 8.04B USD, a debt-to-equity ratio of 1.38. Its Piotroski F-score is 5 out of 9, an average reading of its financial health. 8 analysts cover the stock, with an average rating of Buy; their mean price target of 73.50 USD is 8.5% above the current price. The next earnings report is expected on 10 February 2027.